1. The past, present and future of clinical pharmacology

   • F. Sjöqvist

   SPECIAL ARTICLE Pages: 553 - 557

2. Drug–drug interactions of new active substances: mibefradil example

   • J. C. Krayenbühl
   • S. Vozeh
   • P. Dayer

   SPECIAL ARTICLE Pages: 559 - 565

3. The efficacy of ginseng. A systematic review of randomised clinical trials

   • B. K. Vogler
   • M. H. Pittler
   • E. Ernst

   CLINICAL TRIALS Pages: 567 - 575

4. Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily Repro-Dose morphine versus MST Continus

   • S. Peat
   • P. Sweet
   • U. Larsen

   PHARMACODYNAMICS Pages: 577 - 581

5. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions

   • Y. Sekine
   • T. Rikihisa
   • Y. Arakawa

   PHARMACODYNAMICS Pages: 583 - 587

6. Consistency and efficacy of cetirizine (10 mg) versus ebastine (20 mg) at 4 h on skin reactivity

   • A. Purohit
   • C. Duvernelle
   • N. Frossard

   PHARMACODYNAMICS Pages: 589 - 592

7. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin

   • B. Mangold
   • W. Gielsdorf
   • M. R. Marino

   PHARMACOKINETICS AND DISPOSITION Pages: 593 - 598

8. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol

   • L. Pan
   • F. M. Belpaire

   PHARMACOKINETICS AND DISPOSITION Pages: 599 - 604

9. Utilisation of codeine and propoxyphene: geographic and demographic variations in prescribing, prescriber and recipient categories

   • K. Henricson
   • A. Carlsten
   • A. Melander

   PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 605 - 611